UNASSIGNED: A prospective study was designed to include patients with prostate cancer with an indication of postoperative radiotherapy as adjuvant or salvage. A hypofractionated radiotherapy scheme of 51 Gy in 17 fractions was performed with the possibility of treating the pelvis at a dose of 36 Gy in 12 fractions sequentially. Safety was evaluated based on acute and late toxicity [according to the Radiation Therapy Oncology Group (RTOG) scale and Common Terminology Criteria Adverse Events (CTCAE) v4.03], International Prognostic Scoring System (IPSS) over time, and quality of life.
UNASSIGNED: From August 2020 to June 2022, 31 patients completed treatment and were included in this report. 35.5% of patients received elective treatment of the pelvic nodal areas. Most patients reported minimal or low acute toxicity, with an acute gastrointestinal (GI) and genitourinary (GU) grade 3 or greater toxicity of 3.2% and 0%, respectively. The evolution in time of the IPSS remained without significant differences (p = 0.42). With the exception of a significant improvement in the domains of hormonal and sexual symptoms of the Expanded Prostate Cancer Index Composite (EPIC) questionnaire, the rest of the domains [EPIC, European Organization for Research and Treatment of Cancer (EORTC) Core quality of life questionnaire (C-30) and Prostate Cancer module (PR-25)] were maintained without significant differences over time. With a follow-up of 15.4 months, late GI and GU grade 2 toxicity was reported greater than 0% and 9.6%, respectively.
UNASSIGNED: Hypofractionated radiotherapy in postoperative prostate cancer appears to be safe with low reports of relevant acute or late toxicity. Further follow-up is required to confirm these results.
UNASSIGNED: The protocol was approved by the accredited Medical Ethical Committee of Pontificia Universidad Católica de Chile. All participants accepted and wrote informed consent.
■设计了一项前瞻性研究,以纳入有术后放疗指征的前列腺癌患者作为辅助或抢救。在17个部分中进行51Gy的大分割放射治疗方案,并有可能在12个部分中以36Gy的剂量依次治疗骨盆。根据急性和晚期毒性评估安全性[根据放射治疗肿瘤组(RTOG)量表和通用术语标准不良事件(CTCAE)v4.03],随着时间的推移,国际预后评分系统(IPSS),和生活质量。
■从2020年8月至2022年6月,31名患者完成了治疗并纳入本报告。35.5%的患者接受了盆腔淋巴结区域的选择性治疗。大多数患者报告的急性毒性最小或低,急性胃肠道(GI)和泌尿生殖系统(GU)3级或更高的毒性为3.2%和0%,分别。IPSS的时间演变没有显著差异(p=0.42)。除了扩大前列腺癌综合指数(EPIC)问卷的激素和性症状领域的显着改善外,其余领域[EPIC,欧洲癌症研究和治疗组织(EORTC)核心生活质量问卷(C-30)和前列腺癌模块(PR-25)]随着时间的推移没有显着差异。经过15.4个月的随访,晚期GI和GU2级毒性报告大于0%和9.6%,分别。
■前列腺癌术后小分割放疗似乎是安全的,相关急性或晚期毒性的报道较少。需要进一步的随访来确认这些结果。
■该协议由智利天主教大学医学伦理委员会批准。所有参与者接受并写知情同意书。